NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy

被引:1
|
作者
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [1 ]
Tereshko, Yan [1 ]
Gigli, Gian Luigi [3 ]
Pucillo, Carlo Ennio [4 ]
Valente, Mariarosaria [1 ,3 ]
机构
[1] Santa Maria Misericordia Univ Hosp, Clin Neurol Unit, I-33100 Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Neurol Unit, I-33100 Udine, Italy
[3] Univ Udine, Dept Med DMED, Neurol Unit, I-33100 Udine, Italy
[4] Univ Udine, Dept Med DMED, Immunol, I-33100 Udine, Italy
关键词
multiple sclerosis; Ocrelizumab; Rituximab; anti-CD20; NK cells;
D O I
10.3390/ph17020150
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Recently, research on the pathogenesis of multiple sclerosis (MS) has focused on the role of B lymphocytes and the possibility of using specific drugs, such as Ocrelizumab and Rituximab, directed toward these cells to reduce inflammation and to slow disease progression. Objective: We aimed to evaluate the effect of Ocrelizumab/Rituximab on laboratory immune parameters and identify the predictors of treatment responses. Methods: A retrospective single-center study was conducted among patients who received infusion therapy with an anti-CD20 drug to treat MS. Results: A total of 64 patients met the inclusion criteria, with 277 total cycles of therapy studied. Compared with the baseline values, anti-CD20 infusions resulted in absolute-value and percentage decreases in B lymphocyte levels and increased the absolute and percentage levels of NK cells 3 and 5 months after therapy (p < 0.001). After multivariate logistic regression analysis, a reduced percentage level of NK cells 3 months after infusion could predict disease activity 6 months after Ocrelizumab/Rituximab administration (p = 0.041). Conclusions: Lower percentage levels of NK cells 3 months after anti-CD20 infusion correlate with the presence of disease activity 6 months after therapy, confirming a possible protective role of NK cells in MS.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
    Gingele, Stefan
    Jacobus, Thais Langer
    Konen, Franz Felix
    Huemmert, Martin W.
    Suehs, Kurt-Wolfram
    Schwenkenbecher, Philipp
    Ahlbrecht, Jonas
    Moehn, Nora
    Mueschen, Lars H.
    Boenig, Lena
    Alvermann, Sascha
    Schmidt, Reinhold E.
    Stangel, Martin
    Jacobs, Roland
    Skripuletz, Thomas
    CELLS, 2019, 8 (01)
  • [32] Rituximab combination therapy in relapsing multiple sclerosis
    Cross, Anne H.
    Klein, Robyn S.
    Piccio, Laura
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2012, 5 (06) : 311 - 319
  • [33] Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review
    Kelsey, Andrew
    Casinelli, Gabriella
    Tandon, Medha
    Sriwastava, Shitiz
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2021, 13
  • [34] Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
    Angelo Bellinvia
    Elio Prestipino
    Emilio Portaccio
    Lorenzo Razzolini
    Mattia Fonderico
    Roberto Fratangelo
    Laura Tudisco
    Luisa Pastò
    Maria P. Amato
    Neurological Sciences, 2020, 41 : 2939 - 2945
  • [35] Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
    Bellinvia, Angelo
    Prestipino, Elio
    Portaccio, Emilio
    Razzolini, Lorenzo
    Fonderico, Mattia
    Fratangelo, Roberto
    Tudisco, Laura
    Pasto, Luisa
    Amato, Maria P.
    NEUROLOGICAL SCIENCES, 2020, 41 (10) : 2939 - 2945
  • [36] The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis
    Toorop, A. A.
    van Lierop, Z. Y. G. J.
    Strijbis, E. M. M.
    Teunissen, C. E.
    Barkhof, F.
    Uitdehaag, B. M. J.
    van Kempen, Z. L. E.
    Killestein, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [37] BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
    Signoriello, E.
    Bonavita, S.
    Di Pietro, A.
    Abbadessa, G.
    Rossi, F.
    Miele, G.
    Casertano, S.
    Lus, G.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 43
  • [38] Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis
    Challa, Bindu
    Esnakula, Ashwini Kumar
    HISTOPATHOLOGY, 2024, 84 (05) : 765 - 775
  • [39] Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
    Boremalm, M.
    Juto, A.
    Axelsson, M.
    Novakova, L.
    Frisell, T.
    Svenningsson, A.
    Lycke, J.
    Piehl, F.
    Selzer, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (08) : 1060 - 1067
  • [40] Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis
    Kraus, J
    Kuehne, BS
    Tofighi, J
    Frielinghaus, P
    Stolz, E
    Blaes, F
    Laske, C
    Engelhardt, B
    Traupe, H
    Kaps, M
    Oschmann, P
    ACTA NEUROLOGICA SCANDINAVICA, 2002, 105 (04): : 300 - 308